Angiotensin I (human, mouse, rat) |
| Catalog No.GP10087 |
Angiotensin I (human, mouse, rat), a decapeptide hormone, is the precursor of Angiotensin II.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 484-42-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Angiotensin I (human, mouse, rat), a decapeptide hormone, is the precursor of Angiotensin II[1]. Angiotensin I is specifically cleaved to Angiotensin II by the angiotensin-converting enzyme (ACE) in vivo[2]. Angiotensin II activates AT1 and AT2 receptors, raises blood pressure, and stimulates aldosterone release[3]. As a standard tool peptide in renin-angiotensin system (RAS) research, Angiotensin I is widely used in cardiovascular studies of hypertension, heart failure, and kidney disease[4].
In vitro, Treatment of murine peritoneal cells with Angiotensin I (10ng/μl；10 min–6h) results in cooperative conversion to Angiotensin II by mast-cell chymase mMCP-4 and carboxypeptidase A, peaking at 10–30min and degrading by 3h, concomitantly yielding Ang-(1–9), Ang-(5–10) and Ang-(1–7)[5]. Angiotensin I (500µM; 2h pre-incubation followed by 48h co-infection) significantly increases the invasion efficiency of SARS-CoV-2 spike-pseudotyped virus (PVP) into human ACE2-overexpressing HEK-ACE2 cells independently of the Angiotensin II AT1 receptor[6].
In vivo, Angiotensin I (1000ng/kg/min; 4 weeks; s.c. osmotic minipump) induced both thoracic and abdominal aortic aneurysms in Ldlr⁻/⁻ mice, and increased ascending aortic intima area by 2.4-fold and suprarenal abdominal aortic diameter by 1.9-fold[7]. Angiotensin I (0.2µg/g BW; single i.p.; 5min ) increased systolic blood pressure by 28 ± 4mmHg in male C57BL/6J mice[8].
References:
[1] Manabe K, Shirahase H, Usui H, Kurahashi K, Fujiwara M. Endothelium-dependent contractions induced by angiotensin I and angiotensin II in canine cerebral artery. J Pharmacol Exp Ther. 1989;251(1):317-320.
[2] Fuchs S, Xiao HD, Hubert C, et al. Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension. 2008;51(2):267-274.
[3] Mulrow PJ. Angiotensin II and aldosterone regulation. Regul Pept. 1999;80(1-2):27-32.
[4] Lazartigues E, Llorens-Cortes C, Danser AHJ. New Approaches Targeting the Renin-Angiotensin System: Inhibition of Brain Aminopeptidase A, ACE2 Ubiquitination, and Angiotensinogen. Can J Cardiol. 2023;39(12):1900-1912.
[5] Lundequist A, Tchougounova E, Abrink M, Pejler G. Cooperation between mast cell carboxypeptidase A and the chymase mouse mast cell protease 4 in the formation and degradation of angiotensin II. J Biol Chem.
2004;279(31):32339-32344.
[6] Zorad S, Skrabanova M, Zilkova M, et al. Angiotensin I and II Stimulate Cell Invasion of SARS-CoV-2: Potential Mechanism via Inhibition of ACE2 Arm of RAS. Physiol Res. 2024;73(1):27-35.
[7] Sawada H, Kukida M, Chen X, et al. Angiotensin I Infusion Reveals Differential Effects of Angiotensin-Converting Enzyme in Aortic Resident Cells on Aneurysm Formation. Circ J. 2020;84(5):825-829.
[8] Forster P, Wysocki J, Abedini Y, et al. Aminopeptidase A Effect on Angiotensin Peptides and Their Blood Pressure Action. Int J Mol Sci. 2025;26(14):6990.
| Cell experiment [1]: | |
Cell lines | HEK-ACE2 cells |
Preparation Method | The recipient cells (HEK-ACE2) were seeded in density 4×104 cells per well of 96-well plate and cultured overnight in normal growth medium (DMEM, pH=7.6) supplemented with 10% FBS. Next day, the cells were pre-incubated with 500µM Angiotensin I for 2h then SARS-CoV-2 Spike pseudovirus (in 50µl of cultivation medium) was added to the cells. The cells were lysed with 70µl of cell lysis buffer 48h post-infection and 30µl of lysate was used to determine the luciferase activity. |
Reaction Conditions | 500µM; 2h pre-incubation followed by 48h co-infection |
Applications | Angiotensin I significantly reduced the viability of human ACE2-overexpressing HEK-ACE2 cells infected with SARS-CoV-2 spike-pseudotyped virus. |
| Animal experiment [2]: | |
Animal models | Male low density lipoprotein receptor (Ldlr)-/- mice |
Preparation Method | Male low density lipoprotein receptor (Ldlr)-/- mice were fed a standard rodent diet and provided with water purified by reverse osmosis (pH 6.0-6.2). Hypercholesterolemia was induced by feeding a diet supplemented with saturated fat. When mice were 8–16 weeks old, saline, Angiotensin I (1,000ng/kg/min) was infused subcutaneously using osmotic pump (Alzet model 1004 for 4 weeks). Aortas were dissected from the ascending region to iliac bifurcation and placed in 10% (wt/vol) neutrally buffered formalin overnight. After removal of adventitia, aortas were pinned and photographed. To quantify abdominal aortic dilation, maximal ex vivo diameters of suprarenal aortas were measured using ImagePro Plus software. Subsequently, aortas were cut open longitudinally, secured with pins, and imaged. To determine formation of thoracic aortic aneurysms, the intimal area of the ascending aorta was measured. |
Dosage form | 1000ng/kg/min; 4 weeks; s.c. osmotic minipump |
Applications | Angiotensin I induced both thoracic and abdominal aortic aneurysms in Ldlr⁻/⁻ mice, and increased ascending aortic intima area by 2.4-fold and suprarenal abdominal aortic diameter by 1.9-fold. |
References: | |
| Cas No. | 484-42-4 | SDF | |
| Chemical Name | Angiotensin I (human, mouse, rat) | ||
| Canonical SMILES | CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CC4=CN=CN4)C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N | ||
| Formula | C62H89N17O14 | M.Wt | 1296.5 |
| Solubility | ≥129.6mg/mL in DMSO, ≥124.2 mg/mL in Water | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 771.3 μL | 3.8565 mL | 7.7131 mL |
| 5 mM | 154.3 μL | 771.3 μL | 1.5426 mL |
| 10 mM | 77.1 μL | 385.7 μL | 771.3 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *